Table 1 Patient characteristics
From: Fanconi anemia gene variants in therapy-related myeloid neoplasms
Patient characteristics | n (range) |
|---|---|
Median age (years, median, range) | 63 (30–78) |
Sex (M/F) | 9/28 |
Type of t-MN according to the WHO | |
AML | 18 |
MDS | 19 |
RA | 6 |
RAEB-1 | 4 |
RAEB-2 | 9 |
Primary malignancy | |
Hodgkin lymphoma | 7 |
Non-Hodgkin lymphoma | 12 |
Breast cancer | 13 |
Breast and another cancer | 5 |
Karyotype (n=32 pts) | |
Normal | 8 |
Complex | 11 |
Isolated Chr. 7 abnorm. | 4 |
Chr. 5+Chr. 7 abnorm. | 3 |
11q23 | 1 |
Balanced translocation | 2 |
Other | 3 |
Treatment for primary malignancy | |
CHT | 23 |
RT | 1 |
RT+CHT | 13 |
Median latency between primary cytotoxic therapy and t-MN diagnosis (years) | 6 (1.3–32.5) |
Median overall survival (months) | 8 (0.1–88) |
